A Phase 2 interventional study of B244 and Vehicle in Atopic Dermatitis Eczema, sponsored by AOBiome LLC. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-10.
Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 237th largest by enrollment of the 544 interventional ones that give a count, is one of 56 that started in 2018, is one of 202 in phase 2, and was the 231st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 56 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
At Screening and Baseline, all subjects must have atopic dermatitis, as defined by the Hanifin and Rajka criteria, which involves a minimum of 10% and a maximum of 30% body surface area, EASI score of 10 to 21 and pruritus visual analogue scale scores of ≥ 5 points on the VAS scale (at least moderate).
The total duration of the study will be approximately 9 weeks. Participants will report for a Screening visit and if all inclusion criteria are met, subjects will go through a two week washout phase before reporting for a Baseline visit.
Subjects will come in for visits at Day 14 (Week 2), Day 28 (Week 4). A final visit will be conducted at Day 42 (Week 6).
Efficacy will be assessed using Atopic Dermatitis Area and Severity Index (EASI) and Visual Analog Scale (VAS).
Blood and urine samples will be collected for standard safety laboratory tests and effect of the drug on inflammatory biomarkers. Participant's safety will be monitored throughout the study.
Investigators plan to enroll approximately 130 total patients.
Randomization will be 1:1 so that equal number of patients will be treated in each Arm of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 suspension in 30ml/bottle Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day.
Biological: B244
Vehicle, 30ml/bottle Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day.
Biological: Vehicle
B244 suspension
Vehicle suspension
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.
Time frame: Baseline to Day 42
Change in Eczema Area Severity Index (EASI) Score Between the Active and Vehicle Groups
EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.
Time frame: Baseline to Day 28
Change in Visual Analog Scale (VAS) Score for Pruritus Between the Active and Vehicle Group
VAS (Visual Analog Scale) was performed as a measure of pruritus. The VAS is composed of a 10-cm line divided into a scale from 0 to 10, and subjects were to indicate the score that best represented the intensity of their itching over the 24-hour period before each visit where a higher score indicated greater severity in pruritus.
Time frame: Baseline to Day 28
Change in the Skindex 16 Score Between the Active and Vehicle Group
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
Time frame: Baseline to Day 28
Change in the IGA Score Between the Active and Vehicle Groups
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease).
Time frame: Baseline to Day 28
Difference in Actigraphy Scratching Event Count Per Hour During the Night Between the Active and Vehicle Group
Subjects were provided two Actigraphy watches (one on each wrist) to accurately monitor subject's sleep, activity, and itching patterns.
Time frame: Baseline to Day 28
Difference in Biomarkers Between Active and Vehicle Groups.
To evaluate if B244 administration on the skin twice daily for 28 days will affect the levels of immune biomarkers.
Time frame: Baseline and Day 28
Microbial Content
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
Time frame: Baseline and Day 28
| Milestone | B244 | Vehicle |
|---|---|---|
| Started | 61 | 61 |
| Completed | 55 | 51 |
| Not completed | 6 | 10 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.
| Participants | B244 | Vehicle |
|---|---|---|
| At Least 1 Treatment-Related TEAE | 2 | 4 |
| At Least 1 Treatment-Related Grade 3 or 4 TEAE | 0 | 0 |
| At Least 1 Treatment-Related Serious TEAE | 0 | 0 |
EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.
| score on a scale | B244 | Vehicle |
|---|---|---|
| Change in Eczema Area Severity Index (EASI) Score Between the Active and Vehicle Groups | -5.7 ± 4.46 | -5.9 ± 5.90 |
VAS (Visual Analog Scale) was performed as a measure of pruritus. The VAS is composed of a 10-cm line divided into a scale from 0 to 10, and subjects were to indicate the score that best represented the intensity of their itching over the 24-hour period before each visit where a higher score indicated greater severity in pruritus.
| score on a scale | B244 | Vehicle |
|---|---|---|
| Week 2 Change from Baseline | -1.5 ± 2.23 | -0.6 ± 1.92 |
| Week 4 Change from Baseline | -1.8 ± 2.81 | -1.4 ± 2.32 |
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
| score on a scale | B244 | Vehicle |
|---|---|---|
| Change in the Skindex 16 Score Between the Active and Vehicle Group | -0.2 ± 5.74 | -0.8 ± 1.28 |
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease).
| score on a scale | B244 | Vehicle |
|---|---|---|
| Change in the IGA Score Between the Active and Vehicle Groups | -0.6 ± 0.82 | -0.7 ± 0.94 |
Subjects were provided two Actigraphy watches (one on each wrist) to accurately monitor subject's sleep, activity, and itching patterns.
| average scratching events per hour | B244 | Vehicle |
|---|---|---|
| Difference in Actigraphy Scratching Event Count Per Hour During the Night Between the Active and Vehicle Group | -3.4 ± 8.26 | 3 ± 7.92 |
To evaluate if B244 administration on the skin twice daily for 28 days will affect the levels of immune biomarkers.
No measurements were reported for this outcome.
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
No measurements were reported for this outcome.
Collected over Baseline to Week 6.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 | 1/61 (1.6%) | 1/61 (1.6%) | 16/61 (26.2%) |
| Vehicle | 0/61 (0%) | 0/61 (0%) | 14/61 (23%) |
| Event | B244 | Vehicle |
|---|---|---|
| ArteriosclerosisVascular disorders | 1/61 | 0/61 |
| Event | B244 | Vehicle |
|---|---|---|
| HeadacheNervous system disorders | 3/61 | 3/61 |
| BronchitisInfections and infestations | 2/61 | 0/61 |
| Upper respiratory infectionInfections and infestations | 2/61 | 1/61 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/61 | 2/61 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 2/61 | 1/61 |
| PruritusSkin and subcutaneous tissue disorders | 0/61 | 2/61 |
| SuperinfectionInfections and infestations | 1/61 | 0/61 |
| Urinary tract infectionInfections and infestations | 0/61 | 1/61 |
| Viral upper respiratory tract infectionInfections and infestations | 1/61 | 1/61 |
| DermatitisSkin and subcutaneous tissue disorders | 1/61 | 0/61 |
Intent to Treat (ITT) population included all randomized subjects.
| Age, Customized(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| < 30 years | 12 | 12 | 24 |
| ≥ 30 years | 49 | 49 | 98 |
| Sex: Female, Male(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| Female | 36 | 44 | 80 |
| Male | 25 | 17 | 42 |
| Ethnicity (NIH/OMB)(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 10 | 25 |
| Not Hispanic or Latino | 46 | 50 | 96 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 5 | 4 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 25 | 28 | 53 |
| White | 27 | 27 | 54 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Weight(kg) | B244 | Vehicle | Total |
|---|---|---|---|
| Mean | 85.420 ± 24.9020 | 85.542 ± 22.8794 | 85.481 ± 23.8132 |
| BMI(kg/m^2) | B244 | Vehicle | Total |
|---|---|---|---|
| Mean | 30.027 ± 9.2237 | 30.551 ± 7.0286 | 30.289 ± 8.1702 |
| BMI Category(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| <20 kg/m^2 | 5 | 2 | 7 |
| 20 to <25 kg/m^2 | 15 | 12 | 27 |
| 25 to <30 kg/m^2 | 12 | 22 | 34 |
| ≥30 kg/m^2 | 29 | 25 | 54 |
| Smoking History(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| Never | 32 | 39 | 71 |
| Former | 10 | 3 | 13 |
| Current | 19 | 19 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Feb 2019, 13 months.
Results were first posted in Oct 2022, 3 years 7 months after primary completion. A results delay was requested in Jul 2020.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC